| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
|
N Engl J Med
|
2015
|
5.39
|
|
2
|
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
|
Lancet Oncol
|
2013
|
2.72
|
|
3
|
Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio.
|
Cancer
|
2014
|
1.93
|
|
4
|
The changing therapeutic landscape of castration-resistant prostate cancer.
|
Nat Rev Clin Oncol
|
2011
|
1.55
|
|
5
|
Psychosocial effects of cancer cachexia: a systematic literature search and qualitative analysis.
|
J Pain Symptom Manage
|
2012
|
1.50
|
|
6
|
Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer.
|
Crit Rev Oncol Hematol
|
2011
|
1.41
|
|
7
|
Development of therapeutic combinations targeting major cancer signaling pathways.
|
J Clin Oncol
|
2013
|
1.30
|
|
8
|
Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics.
|
Cancer Metastasis Rev
|
2014
|
1.11
|
|
9
|
Evolving classification systems for cancer cachexia: ready for clinical practice?
|
Support Care Cancer
|
2010
|
1.10
|
|
10
|
Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study.
|
Invest New Drugs
|
2014
|
0.86
|
|
11
|
A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours.
|
Eur J Cancer
|
2012
|
0.84
|
|
12
|
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.
|
Future Oncol
|
2014
|
0.82
|
|
13
|
T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein.
|
J Transl Med
|
2013
|
0.81
|
|
14
|
Radiation recall dermatitis with soft tissue necrosis following pemetrexed therapy: a case report.
|
J Med Case Rep
|
2009
|
0.80
|
|
15
|
Management of patients with castration-resistant disease.
|
Hematol Oncol Clin North Am
|
2013
|
0.79
|
|
16
|
First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer.
|
Clin Cancer Res
|
2014
|
0.78
|
|
17
|
Athrombogenic coating of long-term venous catheter for cancer patients: a prospective, randomised, double-blind trial.
|
Ann Hematol
|
2011
|
0.75
|